Vincerx Pharma (VINCW) Stock Analysis

What Vincerx Pharma does

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to identifying and developing therapeutic solutions for pressing unmet needs in cancer care across the United States. The company's lead investigational compound, VIP152, functions as a cyclin-dependent kinase-9 (CDK9) inhibitor, specifically developed to treat patients afflicted with advanced cancer. Beyond its lead program, Vincerx Pharma's preclinical pipeline features VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor indications; and VIP943 and VIP924, both being explored for hematologic malignancies. Founded in 2019, Vincerx Pharma, Inc. has its corporate base in Palo Alto, California.

Key metrics

ETFs linked to VINCW

Broad-market and Healthcare sector ETFs an investor holding Vincerx Pharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how VINCW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Vincerx Pharma?

Vincerx Pharma trades under the ticker VINCW on NASDAQ.

Which exchange is VINCW listed on?

VINCW is listed on NASDAQ.

What sector does Vincerx Pharma operate in?

Vincerx Pharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze VINCW in a portfolio?

PortView shows VINCW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.